{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T20:32:14Z","timestamp":1774989134833,"version":"3.50.1"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2017,4,14]],"date-time":"2017-04-14T00:00:00Z","timestamp":1492128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0175826","type":"journal-article","created":{"date-parts":[[2017,4,14]],"date-time":"2017-04-14T13:42:01Z","timestamp":1492177321000},"page":"e0175826","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":44,"title":["Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany"],"prefix":"10.1371","volume":"12","author":[{"given":"Emma","family":"Sullivan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Piercy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7322-991X","authenticated-orcid":true,"given":"John","family":"Waller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher M.","family":"Black","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumesh","family":"Kachroo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,4,14]]},"reference":[{"key":"ref1","first-page":"1","article-title":"GUIDELINES ON EVALUATION OF SIMILAR BIOTHERAPEUTIC PRODUCTS (SBPs)","year":"2009"},{"key":"ref2","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1) [Internet]. London; 2012 [cited 2016 Jul 29] p. 1\u20139. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003953<\/ext-link>. (Accessed 29 July 2016)"},{"key":"ref3","unstructured":"US Food and Drug Administration. Quality considerations in demonstrating biosimilarity to a reference product: draft guidance [Internet]. 2012 Feb [cited 2016 Jul 29]. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM291134.pdf<\/ext-link>"},{"issue":"5","key":"ref4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.4161\/mabs.25864","article-title":"Approval of the first biosimilar antibodies in Europe","volume":"5","author":"A Beck","year":"2013","journal-title":"mAbs"},{"key":"ref5","unstructured":"McKee S. Hospira launches Remicade biosimilar in major EU markets [Internet]. 2015 [cited 2016 Aug 12]. Available from: http:\/\/www.pharmatimes.com\/news\/hospira_launches_remicade_biosimilar_in_major_eu_markets_971052<\/ext-link>"},{"key":"ref6","unstructured":"Generics and Biosimilars Initiative. Use of biosimilars in Europe differs across countries [Internet]. GaBOnline. 2014 [cited 2016 Jul 11]. Available from: http:\/\/www.gabionline.net\/Reports\/Use-of-biosimilars-in-Europe-differs-across-countries<\/ext-link>"},{"issue":"4","key":"ref7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1600-0609.2010.01566.x","article-title":"Biosimilar agents in oncology\/haematology: from approval to practice","volume":"86","author":"D Niederwieser","year":"2011","journal-title":"Eur J Haematol"},{"key":"ref8","unstructured":"Regulation Rahmenvertrag. German Bundesministerium der Justiz German Social Law book. In: German Bundesministerium der Justiz German Social Law book, \u2018Aut idem\u2019\u00a7 129. 2008. p. section 4 sentence 1."},{"key":"ref9","unstructured":"Home\u2014GaBI Online\u2014Generics and Biosimilars Initiative [Internet]. [cited 2016 Aug 12]. Available from: http:\/\/gabionline.net\/Reports\/UK-biosimilars-uptake-lower-than-in-some-other-EU-countries<\/ext-link>"},{"key":"ref10","article-title":"The impact of biosimilars\u2019 entry in the EU market. Report prepared for the European Commission (Directorate-General for Enterprise and Industry)","author":"J Rovira","year":"2011"},{"issue":"Suppl 4","key":"ref11","first-page":"S1","article-title":"NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives","volume":"9","author":"AD Zelenetz","year":"2011","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"issue":"22","key":"ref12","first-page":"3191","article-title":"Biosimilars: the science of extrapolation. Blood","volume":"124","author":"M Weise","year":"2014","journal-title":"Biosimilars: the science of extrapolation. Blood"},{"issue":"Suppl 1","key":"ref13","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1007\/s11523-011-0193-6","article-title":"What do prescribers think of biosimilars?","volume":"7","author":"MS Aapro","year":"2012","journal-title":"Target Oncol"},{"issue":"2","key":"ref14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5639\/gabij.2014.0302.018","article-title":"Biosimilars naming, label transparency and authority of choice\u2013survey findings among European physicians","volume":"3","author":"RO Dolinar","year":"2014","journal-title":"Generics Biosimilars Initiat J"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/1471-2474-15-333","article-title":"Patient participation in decisions about disease modifying anti-rheumatic drugs: a cross-sectional survey","volume":"15","author":"I Nota","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"issue":"2","key":"ref16","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.drudis.2015.09.008","article-title":"Key strategic factors for stakeholders in the current global biosimilar market","volume":"21","author":"D Casey","year":"2016","journal-title":"Drug Discov Today"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2147\/PPA.S104891","article-title":"Patient attitudes and understanding about biosimilars: an international cross-sectional survey","volume":"10","author":"I Jacobs","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"ref18","unstructured":"European Medicine Agency. Summary of the risk management plan (RMP) for Benepali (etanercept) [Internet]. EMA; 2015 p. 1\u20133. Report No.: EMA\/783235\/2015. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Risk-management-plan_summary\/human\/004007\/WC500196679.pdf<\/ext-link>"},{"key":"ref19","unstructured":"Generics and Biosimilars Initiative. Biosimilars of adalimumab [Internet]. 2014 [cited 2016 Aug 12]. Available from: http:\/\/www.gabionline.net\/Biosimilars\/General\/Biosimilars-of-adalimumab<\/ext-link>"},{"key":"ref20","unstructured":"Pfenex, Biosimilars, and Better Health [Internet]. Pfenex. 2015 [cited 2016 Aug 12]. Available from: http:\/\/www.pfenex.com\/the-pfenex-difference\/<\/ext-link>"},{"key":"ref21","unstructured":"Investor Overview\u2014Investors\u2014EPIRUS Biopharmaceuticals, Inc. [Internet]. [cited 2016 Aug 12]. Available from: http:\/\/ir.epirusbiopharma.com\/<\/ext-link>"},{"key":"ref22","unstructured":"Sandoz\u2019 biosimilar rituximab regulatory submission accepted by European Medicines Agency [Internet]. Novartis. [cited 2016 Aug 12]. Available from: https:\/\/www.novartis.com\/news\/media-releases\/sandoz-biosimilar-rituximab-regulatory-submission-accepted-european-medicines<\/ext-link>"},{"issue":"11","key":"ref23","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","article-title":"Real-world physician and patient behaviour across countries: Disease-Specific Programmes\u2013a means to understand","volume":"24","author":"P Anderson","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"ref24","unstructured":"IMS. Delivering on the Potential of Biosimilar Medicines The Role of Functioning Competitive Markets [Internet]. 2016 Mar p. 1\u201340. Available from: https:\/\/www.imshealth.com\/files\/web\/IMSH%20Institute\/Healthcare%20Briefs\/Documents\/IMS_Institute_Biosimilar_Brief_March_2016.pdf<\/ext-link>"},{"issue":"11","key":"ref25","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.crohns.2014.06.007","article-title":"Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn\u2019s and Colitis Organization","volume":"8","author":"S Danese","year":"2014","journal-title":"J Crohns Colitis"},{"key":"ref26","article-title":"Changes in Biosimilar Knowledge among European Crohn\u2019s Colitis Organization [ECCO] Members: An Updated Survey","author":"S Danese","year":"2016","journal-title":"J Crohns Colitis"},{"key":"ref27","article-title":"Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn\u2019s and Ulcerative Colitis Associations","author":"L Peyrin-Biroulet","year":"2016","journal-title":"J Crohns Colitis"},{"key":"ref28","unstructured":"The British Society for Rheumatology. British Society for Rheumatology Position statement on biosimilar medicines [Internet]. 2015 [cited 2016 Oct 4]. Available from: http:\/\/www.rheumatology.org.uk\/about_bsr\/press_releases\/bsr_supports_the_use_of_biolsimilars_but_recommends_measures_to_monitor_safety.aspx<\/ext-link>"},{"issue":"3","key":"ref29","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s12325-015-0193-5","article-title":"Nomenclature and traceability debate for biosimilars: small-molecule surrogates lend support for distinguishable nonproprietary names","volume":"32","author":"J Chao","year":"2015","journal-title":"Adv Ther"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Waller J, Sullivan E, Piercy J, Black CM, Kachroo S. Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany [Internet]. Patient Preference and Adherence. 2017 [cited 2017 Mar 15]. Available from: https:\/\/www.dovepress.com\/assessing-physician-and-patient-acceptance-of-infliximab-biosimilars-i-peer-reviewed-article-PPA<\/ext-link>","DOI":"10.2147\/PPA.S129333"},{"issue":"2","key":"ref31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.5639\/gabij.2013.0202.023","article-title":"Biosimilars in oncology: current and future perspectives","volume":"2","author":"M Aapro","year":"2013","journal-title":"Generics Biosimilars Initiat J"},{"issue":"7","key":"ref32","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1093\/rheumatology\/kew048","article-title":"Less educated and older patients have reduced access to biologic DMARDs even in a country with highly developed social welfare (Norway): results from Norwegian cohort study NOR-DMARD","volume":"55","author":"P Putrik","year":"2016","journal-title":"Rheumatol Oxf Engl"},{"issue":"11","key":"ref33","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1136\/annrheumdis-2013-203819","article-title":"Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country\u2019s wealth?","volume":"73","author":"P Putrik","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"ref34","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/annrheumdis-2012-202603","article-title":"Inequities in access to biologic and synthetic DMARDs across 46 European countries","volume":"73","author":"P Putrik","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"ref35","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/1756283X16636764","article-title":"Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients","volume":"9","author":"J Jahnsen","year":"2016","journal-title":"Ther Adv Gastroenterol"},{"issue":"Suppl 3","key":"ref36","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1053\/j.seminoncol.2014.03.008","article-title":"Biosimilars in oncology: from development to clinical practice","volume":"41","author":"Tkaczuk KH Rak","year":"2014","journal-title":"Semin Oncol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3389\/fphar.2016.00193","article-title":"Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies","volume":"7","author":"E Moorkens","year":"2016","journal-title":"Front Pharmacol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0175826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T22:48:29Z","timestamp":1569019709000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0175826"}},"subtitle":[],"editor":[{"given":"Michael","family":"Nurmohamed","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,4,14]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,4,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0175826","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,14]]}}}